

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 31927-CIP2	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT: MESSADEK, Jallal	
		FILING DATE:	GROUP:

U.S. PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
742	5 8 8 0 0 9 8	09.03.99	Häussinger			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
742	9 7 0 6 7 9 5	27.02.97	WO			
	0 7 8 1 5 5 4	23.07.96	EPO			
	9 8 1 9 6 9 0	06.11.96	WO			
	9 5 1 5 7 5 0	10.12.93	WO			
	9 7 3 8 6 8 5	12.04.96	WO			
	0 3 4 7 8 6 4	20.06.89	EPO			
	0 0 2 5 7 6 4	30.10.98	WO			
	2 1 0 1 2 2 B	28.09.92	HU			
	1 0 3 2 1 9 8 4	11.12.98	JP			
	0 9 9 0 0 1 6 4	05.12.00	BE			
	0 0 5 1 5 9 6	08.09.00	WO			
749	0 3 4 9 9 0 2	29.06.89	EPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

747		Savi et al.; Article from Entrez-PubMed web page entitled: SR 121787, a new orally active fibrinogen receptor antagonist; Sep, 80(3):469-76.
		Banno et al.; Article from Entrez-PubMed web page entitled: Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist; Eur J Pharmacol 1999 Feb 19; 367 (2-3): 275-82.
		Ramjit et al.; Article from Entrez-PubMed web page entitled: Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis; J Pharmacol Exp Ther 1993, Sep; 266(3): 1501-11.
		Savi et al.; Article from Entrez-PubMed7.htm web page entitled: SR121787, a new orally active fibrinogen receptor antagonist; Thromb Haemost 1998 Sep; 80(3): 469-76.
		Hoffmann et al.; Article from Entrez-PubMed web page entitled: SR 121787, Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist; J Pharmacol Exp Ther 1998 Aug; 286(2): 670-5.
		Packham; Article from Entrez-PubMed web page entitled: Role of platelets in thrombosis and hemostasis; Can J Physiol Pharmacol 1994; Mar; 72(3): 278-84.
		Lynch et al.; Article from Entrez-PubMed web page entitled: Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383; J Pharmacol Exp Ther 1995 Jan; 272(1): 20-32.
748		Savi et al. ; Article from Entrez-PubMed web page entitled: The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403. KATHADA et al. (1997)

FB		Article from Entrez-PubMed web page entitled: antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs. <i>OGAWA et al. (2002) MARCH</i>
		XP-002123170; Database Chemabs 'Online!'; Chemical Abstracts Service, Columbus, OH; ZAPADNYUK, B.I. et al.: "Bile-secretory effect of trimethylglycine in normal and atherosclerotic animals of different ages" retrieved from STN Databas accession no. 107:190742 HCA; abstract & BYULL. EKSP. BIOL. MED. (1987), 104(7), 30-2
		XP002123171; Database Chemabs 'Online!'; Chemical ABstracts Service, Columbus, OH; PANTELEIMONOVA, T.N. et al.: "Effect of trimethylglycine on lipid metabolism in rabbits with experimental atherosclerosis" retrieved from STN; Database accession no. 99:99080 HCA; abstract & FARMAKOL. TOKSIKOL. (MOSCOW) (1983), 46(4), 83-5
		XP-000853747; Fazio B Et al: "Treatment of human atherosclerosis with betaine." MINERVA MED, (1961 APR 25) 52 1511-6., the whole document
		XP-002123167; P.H. List et al.: "HAGERS HANDBUCH DER PHARMAZEUTISCHEN PRAXIS" 1972, SPRINGER-VERLAG, BERLIN HEIDELBERG, NEW YORK, page 431
		XP000853853; "Betaine for homocystinuria." MEDICAL LETTER ON DRUGS AND THERAPEUTICS, (1997); 39/993 (12), the whole document
		XP000853897; WILCKEN D E ET AL: "The natural history of vascular disease in homocystinuria and the effects of treatment." JOURNAL OF INHERITED METABOLIC DISEASE, (1997 JUN) 20 (2) 295-300., the whole document
		XP-002123168; J.E.F. REYNOLDS: "MARTINDALE, The Extra Pharmacopoeia"; 1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON; "Betaine hydrochloride"; page 1679
		XP002123169; "the merck index"; 1996, MERCK & CO, WHITEHOUSE STATIONS, NJ; "Betaine"; page 198
		Mar et al.; Betaine in wine: answer to the French paradox?; Med Hypothese 1999 Nov; 53(5):383-5
		Salamone et al.; Changes in blood coagulation in experimental subacute poisoning with p-dichlorobenzene. The influence of some lipotropic factors; Journal; Answer 13 of 13; Copyright 2003
		XP001080754; Vinson et al.; New Drug Approvals of 1996 - Part 3; University of Mississippi School of Pharmacy; Drug Topics; March 17, 1997; pages 72-81.
		XP-002202249; Napreben; Pharmaprojects; Applied Pharma Research; Company communication, APR, Sep 1995; whole document.
		Matthews et al.; An indirect response model for homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria; copyright 2002 Blackwell Science Ltd. Br J Clin Pharmacol, 54, 140-146.
MA		Schwahn et al.; Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria; copyright 2003 Blackwell Science Ltd. Br J Clin Pharmacol, 55, 6-13.
		Naproxen monography from http://ndist.com/ ; Clinical Pharmacology; 2 pages <i>TJB</i>
FA		Bandfield et al.; Naproxen, Naproxen Sodium, and Naproxen Betainate Sodium Monohydrate Salts; Pharmaceutics I; April 14, 2001; 5 pages
FB		van Hecken et al.; Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers; Drug Metabol Drug Interact 1998; 14 (3): 193-205.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.